Exclusive distribution contract for tinniwell in Turkey
Egnach, September 25, 2024 – Starting in October 2024, the tinniwell will also be available in Turkey. An exclusive distribution agreement for the tinnitus therapy device has now been concluded. With an average of about 15% of the population affected by tinnitus, there is a market potential of approximately 13 million patients.
In the near future, further country licenses are expected to be finalized.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company that was founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for inquiries:
Resaphene Suisse AG
Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668